AU2015213900B2 - Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists - Google Patents
Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists Download PDFInfo
- Publication number
- AU2015213900B2 AU2015213900B2 AU2015213900A AU2015213900A AU2015213900B2 AU 2015213900 B2 AU2015213900 B2 AU 2015213900B2 AU 2015213900 A AU2015213900 A AU 2015213900A AU 2015213900 A AU2015213900 A AU 2015213900A AU 2015213900 B2 AU2015213900 B2 AU 2015213900B2
- Authority
- AU
- Australia
- Prior art keywords
- mmol
- carboxylate
- hydrocarbon group
- compound according
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(*)C(CN(C)CC1)C1c1nnn[n]1 Chemical compound CC(*)C(CN(C)CC1)C1c1nnn[n]1 0.000 description 4
- RXNZFHIEDZEUQM-UHFFFAOYSA-N Brc1ncc[s]1 Chemical compound Brc1ncc[s]1 RXNZFHIEDZEUQM-UHFFFAOYSA-N 0.000 description 1
- OGXJEVCPEZGSKJ-UHFFFAOYSA-N C(CC1c2ccn[nH]2)CN1C1CCNCC1 Chemical compound C(CC1c2ccn[nH]2)CN1C1CCNCC1 OGXJEVCPEZGSKJ-UHFFFAOYSA-N 0.000 description 1
- KHHSPOJLJYEDCI-UHFFFAOYSA-N C(CC1c2nnn[nH]2)CN1C1CCNCC1 Chemical compound C(CC1c2nnn[nH]2)CN1C1CCNCC1 KHHSPOJLJYEDCI-UHFFFAOYSA-N 0.000 description 1
- YDKMMXBPUCTFTD-UHFFFAOYSA-N C(CNCC1)C1c1nnc[o]1 Chemical compound C(CNCC1)C1c1nnc[o]1 YDKMMXBPUCTFTD-UHFFFAOYSA-N 0.000 description 1
- RTDUCVVITRHYSA-LLVKDONJSA-N C(C[C@@H]1c2ncc[s]2)CN1C1CCNCC1 Chemical compound C(C[C@@H]1c2ncc[s]2)CN1C1CCNCC1 RTDUCVVITRHYSA-LLVKDONJSA-N 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1=O)=O ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- GMADLJSGNUJUCH-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(CCC1)CC1(F)F)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(CCC1)CC1(F)F)=O GMADLJSGNUJUCH-UHFFFAOYSA-N 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N)=O LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- YGUAGAZZHWMLLO-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1)C1C(CC1)CCN1C(OCc1ccccc1)=O)O Chemical compound CC(C)(C)OC(N(CCC1)C1C(CC1)CCN1C(OCc1ccccc1)=O)O YGUAGAZZHWMLLO-UHFFFAOYSA-N 0.000 description 1
- DMSLPGMAUARSMT-UHFFFAOYSA-N CC(C)(C)OC(N1C(C2CCNCC2)c2ccccc2C1)=O Chemical compound CC(C)(C)OC(N1C(C2CCNCC2)c2ccccc2C1)=O DMSLPGMAUARSMT-UHFFFAOYSA-N 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N CC(C)(C)OC(NN)=O Chemical compound CC(C)(C)OC(NN)=O DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- BZCFPFKKLNRCPS-UHFFFAOYSA-N CC(N1CC(C2)(CC2N(CC2)CCC2=C2NCCC2)CC1)OC Chemical compound CC(N1CC(C2)(CC2N(CC2)CCC2=C2NCCC2)CC1)OC BZCFPFKKLNRCPS-UHFFFAOYSA-N 0.000 description 1
- NOVPYXFYTVFXEP-UHFFFAOYSA-N CC(N1CC(C2)(CC2N(CC2)CCC2C2NCCCC2)CC1)=C Chemical compound CC(N1CC(C2)(CC2N(CC2)CCC2C2NCCCC2)CC1)=C NOVPYXFYTVFXEP-UHFFFAOYSA-N 0.000 description 1
- JRAQWFWKNASODJ-GPJFCIFZSA-N CC(N1CC(C2)(CC2N(CC2)CCC2[C@H]2N(CC(F)(F)F)CCC2)CC1)=C Chemical compound CC(N1CC(C2)(CC2N(CC2)CCC2[C@H]2N(CC(F)(F)F)CCC2)CC1)=C JRAQWFWKNASODJ-GPJFCIFZSA-N 0.000 description 1
- SOFPALOKSUJISL-UHFFFAOYSA-N CCOC(N1CC(C2)(CC2N(CC2)CCC2C2NCCC2)CC1)=O Chemical compound CCOC(N1CC(C2)(CC2N(CC2)CCC2C2NCCC2)CC1)=O SOFPALOKSUJISL-UHFFFAOYSA-N 0.000 description 1
- VTNPTBFHPQBIKL-OBXNSHGQSA-N CCOC(N1CC(C2)(CC2N(CC2)CCC2N(CC(C2)(F)F)[C@H]2C(NC)=O)CC1)=C Chemical compound CCOC(N1CC(C2)(CC2N(CC2)CCC2N(CC(C2)(F)F)[C@H]2C(NC)=O)CC1)=C VTNPTBFHPQBIKL-OBXNSHGQSA-N 0.000 description 1
- ZEYUGSOCURRXDF-UHFFFAOYSA-N CCOC(N1CC(C2)(CC2N(CC2)CCC2c2ncccc2C)CC1)=C Chemical compound CCOC(N1CC(C2)(CC2N(CC2)CCC2c2ncccc2C)CC1)=C ZEYUGSOCURRXDF-UHFFFAOYSA-N 0.000 description 1
- CGBLHVUOZYKMCK-UHFFFAOYSA-N CCOC(N1CC(C2)(CC2N(CCC2)CCCC22NCCC2)CC1)=O Chemical compound CCOC(N1CC(C2)(CC2N(CCC2)CCCC22NCCC2)CC1)=O CGBLHVUOZYKMCK-UHFFFAOYSA-N 0.000 description 1
- YAEGLMIBYIVZJZ-MRVPVSSYSA-N CC[C@H](CO1)N(C2CCNCC2)C1=O Chemical compound CC[C@H](CO1)N(C2CCNCC2)C1=O YAEGLMIBYIVZJZ-MRVPVSSYSA-N 0.000 description 1
- FMVBKBKOFVMNBG-UHFFFAOYSA-N CCc1nnc(C2CCN(C)CC2)[nH]1 Chemical compound CCc1nnc(C2CCN(C)CC2)[nH]1 FMVBKBKOFVMNBG-UHFFFAOYSA-N 0.000 description 1
- POTGJWFWPGMYQU-UHFFFAOYSA-N CN(CC1)CCC1N(CCCCC1)C1=O Chemical compound CN(CC1)CCC1N(CCCCC1)C1=O POTGJWFWPGMYQU-UHFFFAOYSA-N 0.000 description 1
- RPYSGPRTWAWWKK-UHFFFAOYSA-N COC(C(C1)NCC1(F)F)=O Chemical compound COC(C(C1)NCC1(F)F)=O RPYSGPRTWAWWKK-UHFFFAOYSA-N 0.000 description 1
- TUHWWSSACZIKGL-UHFFFAOYSA-N COC(C(CCCCC1)N1C1CCNCC1)=O Chemical compound COC(C(CCCCC1)N1C1CCNCC1)=O TUHWWSSACZIKGL-UHFFFAOYSA-N 0.000 description 1
- XZXVCMHKFUIDRV-LLVKDONJSA-N COC([C@@H](CCCC1)N1C1CCNCC1)=O Chemical compound COC([C@@H](CCCC1)N1C1CCNCC1)=O XZXVCMHKFUIDRV-LLVKDONJSA-N 0.000 description 1
- VVLRTXDYAWKZDG-UHFFFAOYSA-N Cc1nnn[n]1C1CCN(C)CC1 Chemical compound Cc1nnn[n]1C1CCN(C)CC1 VVLRTXDYAWKZDG-UHFFFAOYSA-N 0.000 description 1
- DRGIBGLITUBVOS-UHFFFAOYSA-N Cc1nnn[n]1C1CCNCC1 Chemical compound Cc1nnn[n]1C1CCNCC1 DRGIBGLITUBVOS-UHFFFAOYSA-N 0.000 description 1
- XPPFWBVTWIQNJV-UHFFFAOYSA-N O=S(OCC(F)(F)F)(S(F)(F)F)=O Chemical compound O=S(OCC(F)(F)F)(S(F)(F)F)=O XPPFWBVTWIQNJV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019201579A AU2019201579B2 (en) | 2014-02-06 | 2019-03-07 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
| AU2020277225A AU2020277225A1 (en) | 2014-02-06 | 2020-11-26 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1402013.5 | 2014-02-06 | ||
| GBGB1402013.5A GB201402013D0 (en) | 2014-02-06 | 2014-02-06 | Pharmaceutical compounds |
| GBGB1416622.7A GB201416622D0 (en) | 2014-09-19 | 2014-09-19 | Pharmaceutical compounds |
| GB1416622.7 | 2014-09-19 | ||
| PCT/GB2015/050331 WO2015118342A1 (en) | 2014-02-06 | 2015-02-06 | Bicyclic aza compounds as muscarinic m1 receptor agonists. |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019201579A Division AU2019201579B2 (en) | 2014-02-06 | 2019-03-07 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015213900A1 AU2015213900A1 (en) | 2016-08-11 |
| AU2015213900B2 true AU2015213900B2 (en) | 2018-12-13 |
Family
ID=52465550
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015213900A Active AU2015213900B2 (en) | 2014-02-06 | 2015-02-06 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
| AU2019201579A Active AU2019201579B2 (en) | 2014-02-06 | 2019-03-07 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
| AU2020277225A Abandoned AU2020277225A1 (en) | 2014-02-06 | 2020-11-26 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019201579A Active AU2019201579B2 (en) | 2014-02-06 | 2019-03-07 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
| AU2020277225A Abandoned AU2020277225A1 (en) | 2014-02-06 | 2020-11-26 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US9670183B2 (enExample) |
| EP (3) | EP3406609B1 (enExample) |
| JP (7) | JP6479029B2 (enExample) |
| KR (1) | KR102352388B1 (enExample) |
| CN (2) | CN106458986B (enExample) |
| AU (3) | AU2015213900B2 (enExample) |
| BR (1) | BR112016017979B1 (enExample) |
| CA (1) | CA2938169C (enExample) |
| CL (1) | CL2016001983A1 (enExample) |
| CY (1) | CY1120834T1 (enExample) |
| DK (2) | DK3102568T3 (enExample) |
| ES (2) | ES2688548T3 (enExample) |
| FI (1) | FI3406609T3 (enExample) |
| HR (2) | HRP20181499T1 (enExample) |
| HU (1) | HUE068301T2 (enExample) |
| IL (1) | IL247117B (enExample) |
| LT (2) | LT3406609T (enExample) |
| MX (2) | MX393637B (enExample) |
| NZ (1) | NZ723103A (enExample) |
| PH (1) | PH12016501570A1 (enExample) |
| PL (2) | PL3102568T3 (enExample) |
| PT (2) | PT3406609T (enExample) |
| RS (2) | RS57843B1 (enExample) |
| RU (1) | RU2685230C2 (enExample) |
| SA (1) | SA516371614B1 (enExample) |
| SG (1) | SG11201606269WA (enExample) |
| SI (2) | SI3102568T1 (enExample) |
| SM (1) | SMT202400446T1 (enExample) |
| UA (1) | UA122121C2 (enExample) |
| WO (1) | WO2015118342A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014KN01075A (enExample) | 2011-11-18 | 2015-10-09 | Heptares Therapeutics Ltd | |
| CN110101699A (zh) | 2013-03-15 | 2019-08-09 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物 |
| FI3406609T3 (fi) * | 2014-02-06 | 2024-09-10 | Nxera Pharma Uk Ltd | Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| CN106687445A (zh) | 2014-09-17 | 2017-05-17 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物 |
| KR102824411B1 (ko) | 2015-02-27 | 2025-06-23 | 베르선 코포레이션 | 세린 프로테아제 저해제로서의 치환된 피라졸 화합물 |
| GB201504675D0 (en) | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513740D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| GB201513742D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513743D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| TW201726675A (zh) | 2015-12-23 | 2017-08-01 | 默沙東藥廠 | M4毒蕈鹼乙醯膽鹼受體之異位調節劑6,7-二氫-5h-吡咯并[3,4-b]吡啶-5-酮 |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| PL3478679T3 (pl) | 2016-07-01 | 2021-10-25 | Pfizer Inc. | Pochodne 5,7-dihydro-pirolopirydyny do leczenia chorób neurologicznych i neurodegeneracyjnych |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| GB201709652D0 (en) | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US11274100B2 (en) | 2017-06-21 | 2022-03-15 | Daiichi Sankyo Company, Limited | EP300/CREBBP inhibitor |
| WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000237A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000236A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| CN110944999A (zh) * | 2017-08-01 | 2020-03-31 | 勃林格殷格翰国际有限公司 | 中间体化合物和方法 |
| US10501483B2 (en) | 2017-10-24 | 2019-12-10 | Allergan, Inc. | Enamines and diastereo-selective reduction of enamines |
| US11325896B2 (en) | 2017-12-20 | 2022-05-10 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| DK3768669T3 (da) | 2018-03-23 | 2023-04-24 | Pfizer | Piperazinazaspiroderivater |
| GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| JOP20220082A1 (ar) | 2019-10-09 | 2023-01-30 | Novartis Ag | مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 |
| CR20220153A (es) * | 2019-10-09 | 2022-05-03 | Novartis Ag | Derivados de 2–azaespiro [3.4] octano como agonistas de m4 |
| ES2983860T3 (es) | 2019-12-06 | 2024-10-25 | Neurocrine Biosciences Inc | Antagonistas del receptor muscarínico 4 y métodos de uso |
| CN115362156A (zh) * | 2020-02-05 | 2022-11-18 | 纽罗克里生物科学有限公司 | 毒蕈碱性受体4拮抗剂及使用方法 |
| US11912705B2 (en) * | 2020-08-20 | 2024-02-27 | The Corporation Of Mercer University | Cathinone derivatives, pharmaceutical formulations, and methods |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| HRP20251427T1 (hr) | 2022-08-04 | 2025-12-19 | Nxera Pharma Uk Limited | Oblici citratne soli agonista muskarinskih receptora |
| AU2023341169A1 (en) * | 2022-09-16 | 2025-03-13 | Cerevel Therapeutics, Llc | M4 activators/modulators and uses thereof |
| KR20250133755A (ko) * | 2023-01-12 | 2025-09-08 | 세레벨 쎄라퓨틱스, 엘엘씨 | M4 활성제/조절제로서의 스피로 유도체 및 이의 용도 |
| WO2024158645A1 (en) * | 2023-01-24 | 2024-08-02 | Neurocrine Biosciences, Inc. | Deuterated compounds |
| CN116496195A (zh) * | 2023-05-10 | 2023-07-28 | 南京优氟医药科技有限公司 | 一种（r）-4,4-二氟代吡咯烷-2-羧酸的制备方法 |
| WO2025030095A1 (en) | 2023-08-03 | 2025-02-06 | Neurocrine Biosciences, Inc. | Methods of synthesis |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070054911A1 (en) * | 2005-03-28 | 2007-03-08 | Ioana Drutu | Muscarinic modulators |
| WO2007100670A1 (en) * | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Spiro condensed piperidnes as modulators of muscarinic receptors |
| CN101874020A (zh) * | 2007-09-11 | 2010-10-27 | 阿斯利康(瑞典)有限公司 | 作为毒蕈碱受体激动剂的哌啶衍生物 |
| WO2013072705A1 (en) * | 2011-11-18 | 2013-05-23 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| WO2014045031A1 (en) * | 2012-09-18 | 2014-03-27 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| AU2206699A (en) | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| CA2444595A1 (en) * | 2001-04-20 | 2002-10-31 | Banyu Pharmaceutical Co., Ltd. | Benzimidazolone derivatives |
| MXPA06013842A (es) * | 2004-05-28 | 2007-03-01 | Vertex Pharma | Moduladores de receptores muscarinicos. |
| KR20080087841A (ko) | 2005-12-22 | 2008-10-01 | 버텍스 파마슈티칼스 인코포레이티드 | 무스카린 수용체의 조절제 |
| CA2643320A1 (en) | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| BRPI0708524A2 (pt) * | 2006-03-03 | 2011-05-31 | Novartis Ag | compostos de n-formil hidroxilamina |
| GB0706188D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| MX2011004340A (es) | 2008-10-29 | 2011-05-23 | Gruenenthal Gmbh | Espiroaminas sustituidas. |
| FR2945531A1 (fr) | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| WO2012020813A1 (ja) * | 2010-08-10 | 2012-02-16 | 大日本住友製薬株式会社 | 縮環ピロリジン誘導体 |
| ES2717680T3 (es) | 2013-04-30 | 2019-06-24 | Glaxosmithkline Ip No 2 Ltd | Potenciador de inhibidores del homólogo de Zeste 2 |
| EA035848B1 (ru) | 2014-02-06 | 2020-08-20 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b |
| CA2945693C (en) | 2014-02-06 | 2020-06-16 | Riboscience Llc | 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication |
| FI3406609T3 (fi) | 2014-02-06 | 2024-09-10 | Nxera Pharma Uk Ltd | Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina |
| AP2017009803A0 (en) | 2014-09-19 | 2017-03-31 | Bayer Pharma AG | Benzyl substituted indazoles as bub1 inhibitors |
| CN111909130B (zh) | 2014-09-19 | 2023-10-31 | 福马治疗股份有限公司 | 作为突变型异柠檬酸脱氢酶抑制剂的吡啶-2(1h)-酮喹啉酮衍生物 |
| CN106687456B (zh) | 2014-09-19 | 2019-12-03 | 葛兰素史密斯克莱知识产权发展有限公司 | 可溶性鸟苷酸环化酶活化剂及它们的用途 |
-
2015
- 2015-02-06 FI FIEP18179258.1T patent/FI3406609T3/fi active
- 2015-02-06 CN CN201580017993.6A patent/CN106458986B/zh active Active
- 2015-02-06 SI SI201530399T patent/SI3102568T1/sl unknown
- 2015-02-06 PT PT181792581T patent/PT3406609T/pt unknown
- 2015-02-06 KR KR1020167024572A patent/KR102352388B1/ko active Active
- 2015-02-06 CA CA2938169A patent/CA2938169C/en active Active
- 2015-02-06 CN CN201910003375.6A patent/CN109851610B/zh active Active
- 2015-02-06 DK DK15703826.6T patent/DK3102568T3/en active
- 2015-02-06 LT LTEP18179258.1T patent/LT3406609T/lt unknown
- 2015-02-06 UA UAA201609185A patent/UA122121C2/uk unknown
- 2015-02-06 HU HUE18179258A patent/HUE068301T2/hu unknown
- 2015-02-06 ES ES15703826.6T patent/ES2688548T3/es active Active
- 2015-02-06 RU RU2016133684A patent/RU2685230C2/ru active
- 2015-02-06 WO PCT/GB2015/050331 patent/WO2015118342A1/en not_active Ceased
- 2015-02-06 PT PT15703826T patent/PT3102568T/pt unknown
- 2015-02-06 AU AU2015213900A patent/AU2015213900B2/en active Active
- 2015-02-06 MX MX2020001236A patent/MX393637B/es unknown
- 2015-02-06 JP JP2016550483A patent/JP6479029B2/ja active Active
- 2015-02-06 NZ NZ723103A patent/NZ723103A/en unknown
- 2015-02-06 MX MX2016010322A patent/MX371529B/es active IP Right Grant
- 2015-02-06 RS RS20181127A patent/RS57843B1/sr unknown
- 2015-02-06 SG SG11201606269WA patent/SG11201606269WA/en unknown
- 2015-02-06 PL PL15703826T patent/PL3102568T3/pl unknown
- 2015-02-06 HR HRP20181499TT patent/HRP20181499T1/hr unknown
- 2015-02-06 LT LTEP15703826.6T patent/LT3102568T/lt unknown
- 2015-02-06 US US15/117,018 patent/US9670183B2/en active Active
- 2015-02-06 PL PL18179258.1T patent/PL3406609T3/pl unknown
- 2015-02-06 EP EP18179258.1A patent/EP3406609B1/en active Active
- 2015-02-06 HR HRP20241145TT patent/HRP20241145T1/hr unknown
- 2015-02-06 EP EP15703826.6A patent/EP3102568B1/en active Active
- 2015-02-06 SI SI201532034T patent/SI3406609T1/sl unknown
- 2015-02-06 BR BR112016017979-0A patent/BR112016017979B1/pt active IP Right Grant
- 2015-02-06 RS RS20240960A patent/RS65894B1/sr unknown
- 2015-02-06 SM SM20240446T patent/SMT202400446T1/it unknown
- 2015-02-06 ES ES18179258T patent/ES2986327T3/es active Active
- 2015-02-06 EP EP24177415.7A patent/EP4413985A3/en active Pending
- 2015-02-06 DK DK18179258.1T patent/DK3406609T3/da active
-
2016
- 2016-08-04 SA SA516371614A patent/SA516371614B1/ar unknown
- 2016-08-04 IL IL247117A patent/IL247117B/en active IP Right Grant
- 2016-08-05 CL CL2016001983A patent/CL2016001983A1/es unknown
- 2016-08-08 PH PH12016501570A patent/PH12016501570A1/en unknown
-
2017
- 2017-05-10 US US15/591,605 patent/US9926297B2/en active Active
-
2018
- 2018-02-22 US US15/902,537 patent/US10196380B2/en active Active
- 2018-09-27 CY CY181100996T patent/CY1120834T1/el unknown
- 2018-12-12 US US16/217,570 patent/US10385039B2/en active Active
-
2019
- 2019-02-01 JP JP2019017086A patent/JP6774513B2/ja active Active
- 2019-03-07 AU AU2019201579A patent/AU2019201579B2/en active Active
- 2019-07-01 US US16/459,179 patent/US10689368B2/en active Active
-
2020
- 2020-06-17 US US16/904,099 patent/US10961225B2/en active Active
- 2020-10-05 JP JP2020168341A patent/JP2021006571A/ja not_active Withdrawn
- 2020-11-26 AU AU2020277225A patent/AU2020277225A1/en not_active Abandoned
-
2023
- 2023-04-03 JP JP2023060030A patent/JP7652829B2/ja active Active
- 2023-05-02 JP JP2023076024A patent/JP7652832B2/ja active Active
- 2023-05-02 JP JP2023076025A patent/JP7652833B2/ja active Active
-
2025
- 2025-03-14 JP JP2025041135A patent/JP2025085736A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070054911A1 (en) * | 2005-03-28 | 2007-03-08 | Ioana Drutu | Muscarinic modulators |
| WO2007100670A1 (en) * | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Spiro condensed piperidnes as modulators of muscarinic receptors |
| CN101874020A (zh) * | 2007-09-11 | 2010-10-27 | 阿斯利康(瑞典)有限公司 | 作为毒蕈碱受体激动剂的哌啶衍生物 |
| WO2013072705A1 (en) * | 2011-11-18 | 2013-05-23 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| WO2014045031A1 (en) * | 2012-09-18 | 2014-03-27 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists |
| US9266857B2 (en) * | 2012-09-18 | 2016-02-23 | Heptares Therapeutics Limited | Bicyclic AZA compounds as muscarinic M1 receptor agonists |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10961225B2 (en) | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | |
| CA2994143C (en) | Muscarinic agonists | |
| HK40114593A (en) | Pharmaceutical compounds | |
| RU2811601C1 (ru) | Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов | |
| RU2811601C9 (ru) | Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов | |
| HK1231473B (en) | Bicyclic aza compounds as muscarinic m1 receptor agonists | |
| HK40007500A (en) | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| HB | Alteration of name in register |
Owner name: NXERA PHARMA UK LIMITED Free format text: FORMER NAME(S): HEPTARES THERAPEUTICS LIMITED |